{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:10:05Z","timestamp":1747635005153,"version":"3.40.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Internal Bridge Funding program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02376-2","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:45:44Z","timestamp":1747633544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A fundamentally new direction in embolization using reactive chemistry in a swine model"],"prefix":"10.1038","volume":"15","author":[{"given":"Erik","family":"Cressman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Stolley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhneet","family":"Warar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie W.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2376_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/00365521.2020.1718747","volume":"55","author":"S Lang","year":"2020","unstructured":"Lang, S. et al. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand. J. Gastroenterol. 55, 222\u2013227. https:\/\/doi.org\/10.1080\/00365521.2020.1718747 (2020).","journal-title":"Scand. J. Gastroenterol."},{"key":"2376_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456. https:\/\/doi.org\/10.1038\/s41586-021-03362-0 (2021).","journal-title":"Nature"},{"key":"2376_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo, M. et al. IMbrave150: efficacy and safety of Atezolizumab plus bevacizumab versus Sorafenib in patients with Barcelona clinic liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the phase III study. Liver Cancer. 12, 238\u2013250. https:\/\/doi.org\/10.1159\/000528272 (2023).","journal-title":"Liver Cancer"},{"key":"2376_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","volume":"10","author":"CAM Fulgenzi","year":"2024","unstructured":"Fulgenzi, C. A. M. et al. Immunotherapy vs best supportive care for patients with hepatocellular Cancer with Child-Pugh B dysfunction. JAMA Oncol. 10, 1253\u20131258. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2166 (2024).","journal-title":"JAMA Oncol."},{"key":"2376_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000521837","volume":"67","author":"CAM Fulgenzi","year":"2022","unstructured":"Fulgenzi, C. A. M. et al. New frontiers in the medical therapy of hepatocellular carcinoma. Chemotherapy 67, 164\u2013172. https:\/\/doi.org\/10.1159\/000521837 (2022).","journal-title":"Chemotherapy"},{"key":"2376_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0375","volume":"85","author":"Y Huang","year":"2024","unstructured":"Huang, Y. & Yu, W. Advances in immune checkpoint therapy in hepatocellular carcinoma. Br. J. Hosp. Med. (Lond). 85, 1\u201321. https:\/\/doi.org\/10.12968\/hmed.2024.0375 (2024).","journal-title":"Br. J. Hosp. Med. (Lond)"},{"key":"2376_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172. https:\/\/doi.org\/10.1038\/s41571-021-00573-2 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2376_CR8","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-203","author":"M Kudo","year":"2021","unstructured":"Kudo, M. Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. Hepatobiliary Surg. Nutr. https:\/\/doi.org\/10.21037\/hbsn-21-203 (2021).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"2376_CR9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/HEP.0000000000000205","volume":"77","author":"G Cabibbo","year":"2023","unstructured":"Cabibbo, G., Celsa, C., Alimenti, E. & Iavarone, M. Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the Moon. Hepatology 77, 1074\u20131077. https:\/\/doi.org\/10.1097\/HEP.0000000000000205 (2023).","journal-title":"Hepatology"},{"key":"2376_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00270-022-03072-8","volume":"45","author":"B Guiu","year":"2022","unstructured":"Guiu, B., Garin, E., Allimant, C., Edeline, J. & Salem, R. TARE in hepatocellular carcinoma: from the right to the left of BCLC. Cardiovasc. Intervent Radiol. 45, 1599\u20131607. https:\/\/doi.org\/10.1007\/s00270-022-03072-8 (2022).","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"2376_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","volume":"45","author":"E Garin","year":"2022","unstructured":"Garin, E., Guiu, B., Edeline, J., Rolland, Y. & Palard, X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc. Intervent Radiol. 45, 1608\u20131621. https:\/\/doi.org\/10.1007\/s00270-022-03215-x (2022).","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"2376_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018 (2022).","journal-title":"J. Hepatol."},{"key":"2376_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clinimag.2021.05.007","volume":"78","author":"BS Letzen","year":"2021","unstructured":"Letzen, B. S. et al. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clin. Imaging. 78, 194\u2013200. https:\/\/doi.org\/10.1016\/j.clinimag.2021.05.007 (2021).","journal-title":"Clin. Imaging"},{"key":"2376_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jvir.2011.10.022","volume":"23","author":"RC Gaba","year":"2012","unstructured":"Gaba, R. C. et al. Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. J. Vasc Interv Radiol. 23, 265\u2013273. https:\/\/doi.org\/10.1016\/j.jvir.2011.10.022 (2012).","journal-title":"J. Vasc Interv Radiol."},{"key":"2376_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/CEJ.0000000000000623","volume":"30","author":"A Gjoreski","year":"2021","unstructured":"Gjoreski, A. et al. Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. Eur. J. Cancer Prev. 30, 258\u2013266. https:\/\/doi.org\/10.1097\/CEJ.0000000000000623 (2021).","journal-title":"Eur. J. Cancer Prev."},{"key":"2376_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s13304-017-0414-3","volume":"69","author":"M Massani","year":"2017","unstructured":"Massani, M., Stecca, T., Ruffolo, C. & Bassi, N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg. 69, 67\u201373. https:\/\/doi.org\/10.1007\/s13304-017-0414-3 (2017).","journal-title":"Updates Surg."},{"key":"2376_CR17","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","volume":"34","author":"KT Brown","year":"2016","unstructured":"Brown, K. T. et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using Doxorubicin-Eluting microspheres compared with embolization with microspheres alone. J. Clin. Oncol. 34, 2046\u20132053. https:\/\/doi.org\/10.1200\/JCO.2015.64.0821 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2376_CR18","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/hep4.2016","volume":"6","author":"T Shirono","year":"2022","unstructured":"Shirono, T. et al. Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol. Commun. 6, 2594\u20132604. https:\/\/doi.org\/10.1002\/hep4.2016 (2022).","journal-title":"Hepatol. Commun."},{"key":"2376_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00270-024-03779-w","volume":"47","author":"P Lucatelli","year":"2024","unstructured":"Lucatelli, P. et al. Long-Term outcomes of balloon TACE for HCC: an European multicentre Single-Arm retrospective study. Cardiovasc. Intervent Radiol. 47, 1074\u20131082. https:\/\/doi.org\/10.1007\/s00270-024-03779-w (2024).","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"2376_CR20","doi-asserted-by":"publisher","first-page":"111619","DOI":"10.1016\/j.ejrad.2024.111619","volume":"178","author":"C Jing","year":"2024","unstructured":"Jing, C. et al. Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study. Eur. J. Radiol. 178, 111619. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111619 (2024).","journal-title":"Eur. J. Radiol."},{"key":"2376_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/13543784.2022.2008355","volume":"31","author":"ZJ Brown","year":"2022","unstructured":"Brown, Z. J., Hewitt, D. B. & Pawlik, T. M. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin. Investig. Drugs. 31, 379\u2013391. https:\/\/doi.org\/10.1080\/13543784.2022.2008355 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2376_CR22","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.transproceed.2024.08.033","volume":"56","author":"H Radovitch","year":"2024","unstructured":"Radovitch, H. et al. Influence of the radiological response on histological necrosis and on the survival of patients treated with transarterial chemoembolization for hepatocellular carcinoma secondary to cirrhosis on the liver transplantation waiting list. Transpl. Proc. 56, 1774\u20131783. https:\/\/doi.org\/10.1016\/j.transproceed.2024.08.033 (2024).","journal-title":"Transpl. Proc."},{"key":"2376_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jvir.2023.12.009","volume":"35","author":"M Mosenthal","year":"2024","unstructured":"Mosenthal, M. et al. Locoregional therapies for hepatocellular carcinoma prior to liver transplant: comparative pathologic necrosis, radiologic response, and recurrence. J. Vasc Interv Radiol. 35, 506\u2013514. https:\/\/doi.org\/10.1016\/j.jvir.2023.12.009 (2024).","journal-title":"J. Vasc Interv Radiol."},{"key":"2376_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2214\/AJR.22.28385","volume":"220","author":"A Sarwar","year":"2023","unstructured":"Sarwar, A. et al. Factors associated with complete pathologic necrosis of hepatocellular carcinoma on explant evaluation after locoregional therapy: A National analysis using the UNOS database. AJR Am. J. Roentgenol. 220, 727\u2013735. https:\/\/doi.org\/10.2214\/AJR.22.28385 (2023).","journal-title":"AJR Am. J. Roentgenol."},{"key":"2376_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bbcan.2014.08.005","volume":"1846","author":"S Kankotia","year":"2014","unstructured":"Kankotia, S. & Stacpoole, P. W. Dichloroacetate and cancer: new home for an orphan drug? Biochim. Biophys. Acta. 1846, 617\u2013629. https:\/\/doi.org\/10.1016\/j.bbcan.2014.08.005 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"2376_CR26","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1007\/s00330-023-10326-7","volume":"34","author":"M Mendiratta-Lala","year":"2024","unstructured":"Mendiratta-Lala, M. et al. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization. Eur. Radiol. 34, 3284\u20133297. https:\/\/doi.org\/10.1007\/s00330-023-10326-7 (2024).","journal-title":"Eur. Radiol."},{"key":"2376_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2967\/jnumed.109.069278","volume":"51","author":"SA Gulec","year":"2010","unstructured":"Gulec, S. A., Sztejnberg, M. L., Siegel, J. A., Jevremovic, T. & Stabin, M. Hepatic structural dosimetry in (90)Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy. J. Nucl. Med. 51, 301\u2013310. https:\/\/doi.org\/10.2967\/jnumed.109.069278 (2010).","journal-title":"J. Nucl. Med."},{"key":"2376_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jhep.2011.03.024","volume":"55","author":"J Namur","year":"2011","unstructured":"Namur, J. et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J. Hepatol. 55, 1332\u20131338. https:\/\/doi.org\/10.1016\/j.jhep.2011.03.024 (2011).","journal-title":"J. Hepatol."},{"key":"2376_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jvir.2009.10.026","volume":"21","author":"J Namur","year":"2010","unstructured":"Namur, J. et al. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J. Vasc Interv Radiol. 21, 259\u2013267. https:\/\/doi.org\/10.1016\/j.jvir.2009.10.026 (2010).","journal-title":"J. Vasc Interv Radiol."},{"key":"2376_CR30","doi-asserted-by":"publisher","first-page":"e4477","DOI":"10.1002\/jms.4477","volume":"55","author":"C Guo","year":"2020","unstructured":"Guo, C., Baluya, D. L., Thompson, E. A., Whitley, E. M. & Cressman, E. N. K. Correlation of molecular and morphologic effects of thermoembolization in a swine model using mass spectrometry imaging. J. Mass. Spectrom. 55, e4477. https:\/\/doi.org\/10.1002\/jms.4477 (2020).","journal-title":"J. Mass. Spectrom."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02376-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02376-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02376-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:45:44Z","timestamp":1747633544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02376-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02376-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17285"}}